Erdafitinib, a pan-FGFR inhibitor approved in 2019 by the FDA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma, was also recently studied in CC. The gene discussed is FGFR2; the disease is cholangiocarcinoma.